Epygenix Therapeutics, Inc.
  • WHO WE ARE
  • WHAT WE DO
  • OUR TECHNOLOGY
    • CLINICAL TRIAL
    • THERAPEUTIC FOCUS
    • TECHNOLOGY
  • PIPELINE
  • NEWS
  • CONTACT
Select Page

Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

Aug 2, 2021 | News

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

Aug 2, 2021 | News

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

Aug 2, 2021 | News

Read Full Press Release: https://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-200-in-lennox-gastaut-syndrome-301345811.html

Epygenix: Fishing for best in class in epilepsy

May 25, 2021 | News

Read Full Press Release Here: https://www.biocentury.com/article/636563/epygenix-fishing-for-best-in-class-in-epilepsy

Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies

May 3, 2021 | News

Read Full Press Release Here: https://www.fiercepharma.com/sponsored/journey-from-aquarium-to-bedside-to-treat-genetic-epilepsies

Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Nov 12, 2020 | News

Read Full Press Release Here: https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html
« Older Entries

Recent Posts

  • Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
  • Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome
  • Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome
Epygenix

Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.

Biotech Web Design Company

©2021 Epygenix Therapeutics, Inc.

How To Find Us

Epygenix Therapeutics, Inc.
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652

Phone: 1 (201) 940-7377

Fax: 1 (201) 940-7218

info@epygenix.com

Latest News

  • Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
  • Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome
  • Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome